TRexBio
Business Services · California, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
681 Gateway Blvd Fl 4, South San Francis...Phone Number
(650) 567-5582Website
trex.bioRevenue
$14.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
2
1
1
About TRexBio
Founded in 2018, based out of South San Francisco, California, TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. The company's powerful 'deep biology' discovery engine maps human tissue Treg behavior to disease processes, allowing the company to identify and characterize novel targets for therapeutic intervention.Explore more
TRexBio Org Chart
Get the full picture
Sign in to uncover key details.
KR
Senior Director, Translational Medicine
CG
Senior Director, Clinical Operations
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is TRexBio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Click to see if TRexBio had a recent Job posting/layoffs
Earning: See what the market has to say on TRexBio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if TRexBio is spiking on competitors!
Product Launch: Get notified when TRexBio launches new products
Funding: Get notified immidiatlly once TRexBio has new funding data
Congratulate Masked Content for being promoted to Masked Content at TRexBio
TRexBio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if TRexBio has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to TRexBio
Compare insights from companies similar to TRexBio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
51-200
Private
$147.5M
2018
RR
Renuka RamanathanVice President Head of Corporate & Business Development
Company Profile Activity
Activity Insights
TRexBio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
TRexBio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about TRexBio.
TRexBio financials insights
Gather financial insights about TRexBio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series A
$85M
2024
Not Disclosed
$84M
Series B
$84M
2026
Other Financing Round
$50M
TRexBio Tech Stack
A closer look at the technologies used by TRexBio
Most Recent Scoops
Funding
Funding
Hiring Plans
TRexBio has more open roles in Medical & Health than it has had at any time in the past 12 months. Areas of expertise include: Biomarkers, Flow Cytometry, Biochemistry, Pharmacology, Biochemical Assays, and Assay Development.
Hiring Plans
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Funding
Funding
TRexBio News & Media
TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #DeepBiology--TRexBio Expands Leadership Team with Appointments of Ariella Kelman, M.D., as Chief Medical Officer and Brandon Hants, MBA, as Chief Financial OfficerTRexBio: $84 Million (Series B) Closed To Decode Human Tissue Immune Biology
TRex Bio - a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics - announced the closing of an oversubscribed $84 million Series B funding round. This funding was led by Delos Capital, with additional new investors Avego BioScience Capital (“Avego”) and Agent Capital. And existing investors Eli Lilly and Company, SV Health Investors, Pfizer Ventures, Johnson & Johnson (through its venture capital arm, Johnson & Johnson Innovation – JJDC, Inc.), AlexandTRexBio Announces $84 Million Series B
SOUTH SAN FRANCISCO, CA, TRex Bio, a biotechnology company decoding human tissue immune biology to create revolutionary therapeutics, announced the close of an oversubscribed $84 million Series B financing round. The financing was led by Delos Capital.TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
SOUTH SAN FRANCISCO--(BUSINESS WIRE)-- #DeepBiology--TRexBio Announces $84 Million Series B Financing to Advance Pipeline of First-in-Class Immunology Programs into Clinical Development
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding TRexBio
Sign Up For FreeTo access detailed company insights
Founded in 2018, based out of South San Francisco, California, TRexBio is a discovery stage biotechnology company leveraging cutting edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. The company's powerful 'deep biology' discovery eng... Read More
